Summary
DexCom Inc. (DXCM) reported strong financial performance for the third quarter and first nine months of 2023, demonstrating significant revenue and profit growth year-over-year. The company's revenue increased by 27% in the third quarter and 24% for the nine-month period, driven by robust sales volume of its continuous glucose monitoring (CGM) systems, particularly with the ongoing adoption of the G7 system. Gross profit also saw healthy increases, up 26% for the quarter and 22% year-to-date, indicating effective cost management alongside sales growth. Financially, DexCom maintains a solid liquidity position with over $3.2 billion in cash, cash equivalents, and short-term marketable securities as of September 30, 2023. The company generated substantial positive cash flow from operations, underscoring its operational efficiency. Management remains focused on strategic investments in research and development and manufacturing capabilities to support future growth, including international expansion. Despite ongoing patent litigation with Abbott and various market risks, the company's operational and financial performance indicates a positive trajectory.
Financial Highlights
52 data points| Revenue | $975.00M |
| Cost of Revenue | $351.70M |
| Gross Profit | $623.30M |
| R&D Expenses | $131.40M |
| SG&A Expenses | $286.40M |
| Operating Expenses | $417.80M |
| Operating Income | $205.50M |
| Interest Expense | $3.80M |
| Net Income | $120.70M |
| EPS (Basic) | $0.31 |
| EPS (Diluted) | $0.29 |
| Shares Outstanding (Basic) | 386.60M |
| Shares Outstanding (Diluted) | 426.80M |
Key Highlights
- 1Revenue increased by 27% to $975.0 million in Q3 2023 compared to Q3 2022, and by 24% to $2.59 billion for the nine months ended September 30, 2023.
- 2Gross profit increased by 26% to $623.3 million in Q3 2023, with a gross profit margin of 63.9%, slightly down from 64.2% in Q3 2022.
- 3Operating income grew significantly by 39% to $205.5 million in Q3 2023, reflecting strong operational leverage.
- 4Net income rose by 19% to $120.7 million in Q3 2023, with diluted EPS of $0.29.
- 5The company ended Q3 2023 with $3.24 billion in cash, cash equivalents, and short-term marketable securities.
- 6Operating cash flow for the nine months ended September 30, 2023 was $614.9 million, up from $537.0 million in the prior year period.
- 7Selling, general, and administrative expenses increased by 21% in Q3 2023, largely due to higher compensation costs and legal expenses related to patent litigation.